Yescarta Label Update Reshapes Options For Relapsed / Refractory Primary CNS Lymphoma
-
FDA expands access for Yescarta in patients with relapsed or refractory primary CNS lymphoma, removing prior CNS-specific restrictions under the existing large B-cell lymphoma indication.
-
Safety concerns are evolving: While neurotoxicity has long limited CAR-T use in CNS disease, emerging evidence suggests CAR-T can be delivered in carefully selected PCNSL patients without unexpected or unmanageable toxicity.
-
Sequencing remains an open question: As CAR-T enters the treatment landscape for PCNSL, clinicians are now grappling with how best to position it relative to methotrexate-based chemotherapy and autologous stem cell transplant, particularly in early relapse.
Despite advances in high-dose methotrexate–based therapy for primary central nervous system lymphoma (PCNSL), outcomes remain poor for patients with relapsed or refractory disease, with median survival often measured in months and limited treatment options beyond intensive chemotherapy or autologous stem cell transplant. Historically, cellular therapies such as CAR-T cells were excluded in CNS lymphoma due to safety concerns, particularly the risk of neurotoxicity. Recent regulatory updates, however, have opened the door to CAR-T therapy for this high-risk population.
Regulatory Update: Yescarta (axicabtagene ciloleucel)
In February 2026, the FDA revised the label for Yescarta by removing prior “Limitations of Use” related to relapsed or refractory PCNSL. While this does not create a standalone indication for PCNSL, it formally allows clinicians to treat eligible PCNSL patients under the existing large B-cell lymphoma label.
“Previously, we could only use Yescarta for patients with recurrent lymphoma who had secondary CNS involvement—primary CNS lymphoma was excluded,” said Dr. Leslie Popplewell, Medical Director, Hematology and Blood and Marrow Transplant, City of Hope Cancer Center Atlanta.. “This label change is exciting because it formally opens the door for treating patients whose disease originates in the brain.”
Yescarta is a CD19-directed autologous CAR-T therapy initially approved for relapsed or refractory large B-cell lymphoma after at least two prior lines of systemic therapy. Previous labeling excluded PCNSL due to historical concerns about neurotoxicity and the lack of prospective data. The updated label reflects emerging safety and feasibility evidence suggesting CAR-T can be administered in selected PCNSL patients without unexpected safety signals.
Evidence Basis: Limited but Meaningful
The label change is based on early-phase, investigator-initiated studies rather than large pivotal trials, including a phase 1 study (NCT04608487) that enrolled relapsed/refractory PCNSL patients who had previously been excluded from CAR-T trials. Safety data indicated that Yescarta could be delivered without new safety concerns, and toxicities were manageable. “One of the major concerns with CAR T-cell therapy has been neurotoxicity, even when it’s given for DLBCL without brain involvement,” Popplewell said.
Earlier small cohorts and retrospective analyses have shown that CD19 CAR-T cells can traffic into the CNS, produce tumor responses, and trigger cytokine release syndrome or neurotoxicity that is generally reversible.
Randomized, multicenter pivotal trials are still lacking. The evidence remains predominantly early-phase with small patient numbers, and clinicians must weigh potential benefits against limited data.
High Unmet Need in Relapsed/Refractory PCNSL
The removal of PCNSL label restrictions reflects both clinical urgency and evolving evidence. Relapsed or refractory PCNSL carries a poor prognosis, often with median survival measured in months after standard salvage therapy. Conventional treatments, including high-dose methotrexate, whole-brain radiation therapy, and autologous stem cell transplant, are frequently ineffective or not feasible, particularly for older or frail patients.
“Primary CNS lymphoma can be very difficult to treat and can have devastating consequences, depending on where the disease is located in the brain,” Popplewell said. “CAR T-cells are highly effective in DLBCL, and this approval gives us another powerful weapon when lymphoma presents in the CNS.”
Emerging Studies and Future Directions
Research is ongoing to better define CAR-T’s role in PCNSL. Multiple phase 2 trials and registries are evaluating CD19 CAR-T therapy, with a focus on safety, efficacy, CNS trafficking, and management of neurotoxicity. Additional efforts are exploring next-generation CAR-T constructs, dual-target approaches, locally delivered therapies, and rational combinations with CNS-penetrant agents.
At the same time, clinicians are beginning to think about how CAR-T should be sequenced relative to existing approaches.
“We sometimes have good success retreating relapsed PCNSL with methotrexate-based chemotherapy, particularly if the patient had a long first remission, and autologous transplant with thiotepa-based conditioning has traditionally been used in first or second remission,” Popplewell explained. “This new option will require some fine-tuning as we determine how best to sequence CAR T—such as whether Yescarta should be used primarily at early first relapse, similar to systemic DLBCL.”
Bottom Line
The updated FDA labeling for Yescarta represents an important milestone, expanding CAR-T therapy to a previously excluded, high-risk population. While evidence remains early-phase and limited, the change reflects urgent unmet need and growing real-world experience demonstrating feasibility. Ongoing and future trials will be critical to clarify efficacy, safety, and optimal sequencing, and may ultimately pave the way toward a formal FDA indication for CAR-T therapy in CNS lymphoma.
